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Abstract
Background: We aimed to explore relations between symptomatic remission and functionality evaluation in
schizophrenia patients treated with paliperidone extended-release (ER), as seen in a normal day-to-day practice,
using flexible dosing regimens of paliperidone ER. We explored symptomatic remission rate in patients treated
with flexibly dosed paliperidone ER by 8 items of Positive and Negative Syndrome Scale (PANSS) and change of
Personal and Social Performance (PSP) scale.
Method: This was a 12-week multicenter, open-label, prospective clinical study conducted in in-patient and out-
patient populations. Flexible dosing in the range 3-12 mg/day was used throughout the study. All subjects
attended clinic visits on weeks 0, 4, 8, and 12 as usual clinical practice for the 12-week observation period. Data
were summarized with respect to demographic and baseline characteristics, efficacy measurement with PANSS
scale, PSP, and social functioning score, and safety observations. Descriptive statistics were performed to identify
the retention rate at each visit as well as the symptomatic remission rate. Summary statistics of average doses the
subjects received were based on all subjects participating in the study.
Results: A total of 480 patients were enrolled. Among them, 426 patients (88.8%) had evaluation at week 4 and
350 (72.9%) completed the 12-week evaluation. Patients with at least moderate severity of schizophrenia were
evaluated as “mild” or better on PANSS scale by all 8 items after 12 weeks of treatment with paliperidone ER. There
was significant improvement in patients’ functionality as measured by PSP improvement and score changes.
Concerning the other efficacy parameters, PANSS total scale, PSP total scale, and social functioning total scale at
the end of study all indicated statistically significant improvement by comparison with baseline. The safety profile
also demonstrated that paliperidone ER was well-tolerated without clinically significant changes after treatment
administration.
Conclusions: Although the short-term nature of this study may limit the potential for assessing improvements in
function, it is noteworthy that in the present short-term study significant improvements in patient personal and
social functioning with paliperidone ER treatment were observed, as assessed by PSP scale.
Trial Registration: Clinical Trials. PAL-TWN-MA3
Background
Schizophrenia is a severe form of mental illness affecting
about 24 million people worldwide (7 per 1000 adult
population), mostly in the age group 15-35 years.
Although the incidence is low (3/10,000), the prevalence
is high due to chronicity [1]. Deficits in social function-
ing can be observed throughout the course of
schizophrenia: in the early stages, during acute exacer-
bations, and over long-term maintenance treatment.
The early course of schizophrenia typically includes a
prodromal phase characterized by nonspecific symptoms
and behaviors, a formal onset/deteriorative stage with
active psychosis, cognitive impairment, negative symp-
toms, and social deficits, and a period of several years
following the initial episode that often includes repeated
episodes of psychosis with a progressive increase in resi-
dual symptoms and functional decline. There is general
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psychotic episode patients enter a chronic, but relatively
more stable phase with no marked further decline in
functioning or increase in residual symptoms [1-5].
With the advancement of new medications, treatment
goals of patients with schizophrenia were raised. On the
one hand, remission, instead of response was recognized
as the optimal treatment goal for patients with schizo-
phrenia. Research on treatments for schizophrenia
focused predominantly on symptom improvement; how-
ever, outcomes such as cognition, health-related quality
of life, and social functioning are now being recognized
as important indices of treatment success. The Remis-
sion in Schizophrenia Working Group (RSWG) chose 8
items of PANSS (delusions, unusual thought content,
hallucinatory behavior, conceptual disorganization, man-
nerisms/posturing, blunted affect, social withdrawal, and
lack of spontaneity) as determinants for the definition of
remission [6]. Several studies have already implemented
this concept and found that patients achieving remission
status had better performance in neuropsychological
tests and greater social and occupational functions [7-9].
On the other hand, functionality became an important
focus of treatment in psychotic patients. Patients who
returned to normal life were considered as undergoing
“truly recovery” [5]. The Personal and Social Perfor-
mance (PSP) scale, developed to measure patients’ per-
sonal and social functionality, is a convenient tool in
clinical practice. Several clinical trials measured patients’
functioning as study endpoints with this scale [10].
Typically with antipsychotic drugs, dose titration to
the maintenance dose is recommended. Paliperidone is
available in a formulation using extended-release (ER)
osmotic release technology (OROS
®), hereinafter
referred to as paliperidone ER. This formulation was
designed to deliver paliperidone at a controlled rate over
a 24-hour period, resulting in a gradual increase in
plasma concentration after the first intake and low
peak-to-trough fluctuation at steady state [11]. Paliperi-
done is the major metabolite of risperidone. It is a pro-
longed release oral atypical antipsychotic for the
treatment of schizophrenia. Based on preclinical experi-
ments and clinical investigations, paliperidone is an
effective and safe antipsychotic medication for the treat-
ment of schizophrenia. Some studies showed that pali-
peridone ER significantly improved symptoms and
functioning in schizophrenia patients regardless of time
since diagnosis [4,12-15]. The phase III well-controlled
pivotal efficacy and safety studies were performed using
randomly applied fixed dosages (3, 6, 9, 12, or 15 mg/
day) of paliperidone ER. In daily clinical practice, how-
ever, flexible dosing is applied based on the individual
needs of patients. The pivotal studies were also per-
formed in well-defined homogenous groups of subjects
with schizophrenia. In daily clinical practice, however, a
more diverse population is treated, e.g. having higher
rates of comorbidities and/or comedications. Pivotal stu-
dies also used an initial washout period. Therefore, no
data for direct transition from a variety of oral antipsy-
chotics to flexibly dosed paliperidone ER are available
today.
In most treatment-related clinical trials, response,
measured with certain percent improvement of rating
scales, is used as outcome determinant. However,
approaches focusing on psychotic patients’ real life func-
tioning are the main interest of clinical practice. Achiev-
ing symptom-free and normal life ought to be the key
measure in clinical studies. Moreover, understanding
symptom-free function is of great value for treatment
goals in clinical practice. Therefore, we designed this
study to explore symptomatic remission and functional-
ity evaluation in patients treated with paliperidone ER,
as seen in normal day-to-day practice, using flexible
dosing regimens.
Methods
2.1 Study Design
This was a 12-week, multicenter, open-label, prospective
clinical study conducted in inpatients and outpatients.
Throughout the study flexible dosing in the range 3-12
mg/day was used so as to allow investigators to adjust
the dosage of each subject based on individual needs. In
general, the recommended paliperidone ER dose was 6
mg once daily, although some subjects benefited from
lower or higher doses in the recommended dose range.
After obtaining informed consent, baseline characteris-
tics, PANSS scale, PSP, and social functioning scale were
assessed and recorded. Treatment of these subjects was
decided by clinicians’ opinion. As for patients with phar-
macotherapy, dosing was flexible throughout the study
period according to investigators’ discretion based on
individual subjects’ clinical response to and tolerability
of study drug. During the study observation period, sub-
jects attended clinic visits on weeks 0, 4, 8, and 12 as
usual clinical practice. At the preplanned clinic visits,
PANSS and PSP scale, reports of adverse events, and
treatment information were recorded. Subjects could
withdraw from this study at any time; reasons of with-
drawal or loss of follow-up were recorded. The study
was approved by the Institutional Review Board of
Cathay General Hospital (protocol no. PAL-TWN-
MA3).
2.2 Patient Population
Participants were male or female and met DSM-IV diag-
nostic criteria above aged 18 years. They were drug
naïve; their previous treatment was considered unsuc-
cessful due to one or more of the following reasons:
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compliance, and/or other reasons. Subjects or their leg-
ally acceptable representatives had signed an informed
c o n s e n td o c u m e n ti n d i c a t i n gt h a tt h e yu n d e r s t o o dt h e
purpose of and procedures required for the study and
were willing to participate in the study. Female subjects
were postmenopausal for ≥ 1 year, surgically sterile,
abstinent, or, if sexually active, agreed to practice an
effective method of birth control before entry and
throughout the study. Effective methods of birth control
included prescription hormonal contraceptives, contra-
ceptive injections, intrauterine devices, double-barrier
method, contraceptive patch, and male partner steriliza-
tion. Female subjects also had a negative urine preg-
nancy test at screening.
Individuals were excluded from the study if the
patients were on clozapine, paliperidone ER, any con-
ventional depot neuroleptic or Risperdal
® Consta
® dur-
ing the last 3 months. Subjects experienced serious
unstable medical condition including known clinically
relevant laboratory abnormalities, history of neuroleptic
malignant syndrome, hypersensitivity to paliperidone ER
or risperidone or inability to swallow the study medica-
tion whole with the aid of water (subjects may not
chew, divide, dissolve, or crush the study medication
because this may affect the release profile) were
excluded. Pregnant or breast-feeding woman and parti-
cipation in another investigational drug trial in the 30
days prior to selection were also excluded from the
study. Of course, employees of the investigator or study
center, persons with direct involvement in the proposed
study or other studies under the direction of that inves-
tigator or study center, or family members of the
employees or the investigator were not allowable.
At each visit subjects received the amount of medica-
tion required until the next visit. Subjects from any oral
antipsychotic medication could be switched to an effec-
tive dose of paliperidone ER without the need for titra-
tion. Subjects could be cross-tapered in different ways
from their previous antipsychotic medication, e.g. a
decrease of the previous antipsychotic drug may occur
at the time of or after initiation of paliperidone ER. The
period of cross-tapering also varied among subjects,
since both dosing and timing of transition depended on
relevant individual subject characteristics such as kind
and severity of current symptoms or adverse events,
course of previous relapses and rehospitalizations, or
type and dose of previous antipsychotic medication (e.g.
with or without anticholinergic and/or sedating
properties).
The neuropsychiatric symptoms of schizophrenia were
assessed by 30-item PANSS scale, which provides a total
score (sum of the scores of all 30 items). Each scale is
rated 1 (absent) to 7 (extreme). The PANSS assessment
was performed by a qualified rater defined as a trained
clinician. If possible, for a given subject, the same rater
assessed this scale at all visits. Subjects were interviewed
at each visit to assess the psychiatric symptoms of
schizophrenia.
The following 8 items were used as determinants for
remission:
-P1 Delusions
-P2 Conceptual disorganization
-P3 Hallucinatory behavior
-G9 Unusual thought content
-G5 Mannerisms and posturing
-N1 Blunted affect
-N4 Social withdrawal
-N6 Lack of spontaneity/flow of conversation
Subjects were rated for their personal and social per-
formance at each visit by PSP scale. This scale assessed
the degree of difficulty a subject exhibited over a 1-
month period within 4 domains of behavior: socially
useful activities, personal and social relations, self-care,
and disturbing and aggressive behavior. The score ran-
ged from 1 to 100, divided into 10 equal intervals to
rate the degree of difficulty (absent to very severe) in
each of the 4 domains. Subjects with scores 71-100 had
a mild degree of difficulty, 31-70 varying degrees of dis-
ability, and ≤ 30 functioning so poorly as to require
intensive supervision.
2.3 Statistical Analysis
Data were analyzed on intent-to-treat (ITT) principle.
All statistical tests were performed with an alpha level
of 0.05. Descriptive analysis of the demographic vari-
ables and other baseline line variables was conducted
using measures of central tendency and variation for
quantitative variables and frequency distributions for
categorical variables. Assessment of safety included
computation of the incidence of AEs and of disconti-
nuation due to AEs, and presented in a frequency distri-
bution table.
Two cohorts were introduced into the study:
- All enrolled subjects (overall);
- An ITT population comprising all enrolled subjects
who received paliperidone ER at least once and provided
≥ 1 post-baseline efficacy measurement.
T h ee f f i c a c ya n a l y s i sw a smainly performed on the
ITT population, but also performed on all enrolled sub-
jects. The safety profile was assessed for the ITT
population.
Data were summarized with respect to demographic
and baseline characteristics, efficacy measurement with
PANSS scale, PSP, and social functioning score, and
safety observations. Descriptive statistics were performed
to identify the retention rate at each visit as well as the
symptomatic remission rate. Summary statistics of
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subjects participating in the study. Descriptive analysis
was performed including frequency and percentage for
categorical parameters, and mean, standard deviation,
minimum, and maximum for continuous parameters.
Descriptive analyses comprised summary statistics and
95% confidence intervals (95%CI). The paired t test was
also performed to compare changes in scores of contin-
uous variables.
The assessment of safety was based mainly on the fre-
quency of AEs. The Medical Dictionary for Regulatory
Activities (MedDRA, Version 12.1) AE dictionary was
used to map AEs to preferred terms and system organ
class. Patients reporting an individual preferred term AE
and the total number of patients reporting at least one
adverse event per system organ class were tabulated.
Each AE based on preferred terminology was counted
only once for a given subject for each group. The fre-
quency and percent AEs (preferred terms and system
organ class) are presented. Descriptive statistics were
provided to evaluate the changes of vital signs at each
scheduled time-point.
Results
A total of 480 patients were enrolled. Among them, a
total of 426 subjects (88.8%) had evaluation at week 4
and 350 (72.9%) completed the 12-week evaluation. The
details of patient disposition are summarized in Figure
1.
Reasons of patient withdrawal before week 4 were AEs
(n = 6), insufficient response (n = 2), ineligible to con-
tinue (n = 15), lost to follow-up (n = 12), consent with-
drawn (n = 16), and noncompliance (n = 3). Therefore
these 54 patients did not have any safety and efficacy
evaluation, resulting in 426 subjects included in the ITT
population.
The initial dose disposition at baseline for these 426
patients was 3 mg/day for 154 patients, 6 mg/day for
232 patients, 9 mg/day for 29 patients, and 12 mg/day
for 11 patients. The average dosage was 5.5 mg/day.
The end doses for 350 subjects who completed the
study were distributed as 45 patients with 3 mg/day, 183
patients with 6 mg/day, 64 patients with 9 mg/day, and
58 patients with 12 mg/day.
The withdrawal reasons are summarized in Table 1.
Overall, 130 subjects (27.1%) discontinued the study
prematurely. The details are as follows: 1 subject (0.2%)
died, 12 subjects (4.8%) withdrew because of adverse
events, 18 (3.8%) subjects withdrew because of insuffi-
cient response, 15 subjects (3.1%) were ineligible to con-
tinue, 28 subjects (5.8%) were lost to follow-up, 35
subjects (7.3%) withdrew their consent, 8 (1.7%) subjects
discontinued because of non-compliance, and 2 subjects
(0.4%) because of other reasons.
Summary statistics of demographic characteristics for
the overall and ITT populations are listed in Table 2. In
the ITT population, there were more men (55.9%) than
women (44.1%). The mean age was 40.4 (range, 17-72)
years; median age was 40 years. Subjects’ schizophrenia
subtype distribution was paranoid 61.7%, undifferen-
tiated 18.9%, disorganized 10.8%, residual 7.3%, catatonic
1.2%, and other subtypes 0.2%. Overall, 33.3% of the
subjects had symptom onset > 10 years but < 20 years.
There were 4.9% of subjects with history of drug abuse.
The results of all enrolled subjects were similar to those
of the ITT population.
The reasons for subjects switching their treatments
are displayed for all enrolled patients and the ITT popu-
lation in Figures 2 and 3, respectively. For the ITT
population, there were 4 subjects who did not receive
any antipsychotics at enrollment. For the remaining 422
subjects, 409 received antipsychotics within 30 days
prior to enrollment. The treatments included oral ris-
peridone for 188 subjects (45.97%), olanzapine for 40
subjects (9.78%), quetiapine for 29 subjects (7.09%), ari-
piprazole for 28 subjects (6.85%), and other treatments
for 166 subjects (40.59%). The major reason of switching
treatment was insufficient efficacy, accounting for a total
of 321 subjects. AEs (82 subjects), noncompliance (42
subjects), and other (2 subjects) were the reasons for
switching. Thirteen subjects received antipsychotics > 30
days prior to enrollment. The switching reasons were
insufficient efficacy (n = 7), noncompliance (n = 6), and
other (n = 1).
Table 3 summarizes previous antipsychotic treatment
received for consecutive 3 months. The most frequently
used antipsychotics were oral risperidone (207 subjects;
48.6%) for the ITT population. The results of all
enrolled subjects were similar to those of the ITT
population.
Table 4 summarizes the complicating diseases for sub-
jects. For the ITT population, the most commonly com-
plained complications were psychiatric (329 subjects;
77.23%), gastrointestinal (145 subjects; 34.04%), and
neurological disorders (104 subjects; 24.41%),
respectively.
Dose disposition of study medication paliperidone ER
of the ITT population and completed population is pre-
sented in Table 5 and Table 6, respectively. In the ITT
population, the number of subjects who started paliperi-
done ER treatment with the initial dose of 3 mg/day
and increased to 6, 9, and 12 mg/day at the end of
study was 69, 17, and 18, respectively. There were 43
and 30 subjects with the initial dose of 6 mg/day and
increased to 9 and 12 mg/day, respectively, at the end of
study, whereas 11 subjects with the initial dose of 9 mg/
day increased to 12 mg/day at the end of study. All sub-
jects with initial dose of 12 mg/day remained on 12 mg/
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a similar dose pattern of study dose disposition.
PANSS and PAP total score both showed significant
improvements after 12-week treatment (PANSS score,
from 89.88 ± 29.20 to 72.72 ± 26.36; PSP score, from
47.07 ± 16.34 to 56.61 ± 14.32; both p < 0.05). The
results of symptomatic remission are summarized in
Figure 4. The symptomatic remission rate was 3.5%
(95%CI, 1.98%, 5.74%) at baseline and improved to
11.7% (95%CI, 8.84%, 15.18%) at the end of study (p <
0.05). The criteria for PSP improvement was at least one
10-point interval on PSP scale. In the ITT population,
subjects showed an increasing PSP improvement after
Figure 1 Patient Disposition. A total of 480 patients were enrolled. Among them, a total of 426 subjects (88.8%) had evaluation at week 4 and
350 (72.9%) completed the 12-week evaluation. The details of patient disposition are summarized.
Table 1 Summary of Withdrawal Reason
Time Overall
(N = 480)
ITT
(N = 426)
Total 130 (27.1%) 76 (17.8%)
Death 1 (0.2%) 1 (0.2%)
Adverse Event 23 (4.8%) 17 (4.0%)
Insufficient Response 18 (3.8%) 16 (3.8%)
Ineligible to Continue 15 (3.1%) 0 (0.0%)
Lost to Follow-up 28 (5.8%) 16 (3.8%)
Withdrew Consent 35 (7.3%) 19 (4.5%)
Non-Compliant 8 (1.7%) 5 (1.2%)
Other 2 (0.4%) 2 (0.5%)
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from 28.1% (95%CI, 23.94%, 32.70%) at week 4 to 47.4%
(95%CI, 42.59%, 52.28%) at the end of study.
AEs with occurrence ≥ 2% during the study are sum-
marized in Table 7. There were 213 patients (50.0%)
with ≥ 1 AE during study. The most commonly experi-
enced AEs were disease progression (33 patients; 7.7%),
upper respiratory tract infection (30 patients; 7.0%),
extrapyramidal disorder (25 patients; 5.2%), insomnia
(17 patients; 4.0%), and constipation (14 patients; 3.3%).
Among the 30 schizophrenia events 27 were recorded as
serious AEs.
Discussion
The severity of the symptoms and long-lasting, chronic
pattern of schizophrenia can impact all areas of daily liv-
ing including work or school, social contacts, and rela-
tionships. Treatment typically involves antipsychotic
medications to stabilize the mood and treat the psycho-
tic symptoms for individual patients. Paliperidone ER
tablets have been approved in the USA and Europe for
the treatment of schizophrenia based on three 6-week,
placebo-controlled clinical trials in patients with acute
symptoms of schizophrenia [13-15]. These studies indi-
cate that paliperidone ER at dosages 3-15 mg/day was
associated with statistically significant improvement
(relative to placebo) in schizophrenia symptoms as
Table 2 Summary of Demographics
Characteristics Overall
(N = 480)
ITT
(N = 426)
Sex Male 262 (54.6%) 238 (55.87%)
Female 218 (45.4%) 188 (44.13%)
Age (years) N < 480 > < 426 >
Mean (SD) 40.3 (10.6) 40.4 (10.6)
Median 39.5 40.0
Min. ~ Max. 16.0 ~ 72.0 17.0 ~ 72.0
Diagnosis Paranoid 300 (62.5%) 263 (61.74%)
Disorganized 46 (9.6%) 46 (10.80%)
Catatonic 6 (1.3%) 5 (1.17%)
Undifferentiated 88 (18.3%) 80 (18.78%)
Residual 37 (7.7%) 31 (7.28%)
Other 3 (0.6%) 1 (0.23%)
In/Out Patient In-patient 218 (45.4%) 207 (48.6%)
Out-Patient 262 (54.6%) 219 (51.4%)
Symptom onset (years) Unspecified 46 (9.6%) 41 (9.62%)
< = 5 95 (19.8%) 78 (18.31%)
> 5~ < = 10 83 (17.3%) 74 (17.37%)
> 10~ < = 20 153 (31.9%) 142 (33.33%)
> 20~ < = 30 78 (16.2%) 67 (15.73%)
> 30 25 (5.2%) 41 (9.62%)
Drug abuse No 437 (91.0%) 386 (90.61%)
Yes 23 (4.8%) 21 (4.93%)
Unspecified 20 (4.2%) 19 (4.46%)
Figure 2 Summary of switching reasons of previous antipsychotic treatment of all enrolled patients. For the enrolled population, there
were 9 subjects who did not receive any antipsychotics at enrollment. For the remaining 471 subjects, 449 received antipsychotics within 30
days prior to enrollment. The treatments included oral risperidone for 201 subjects (44.77%), olanzapine for 41 subjects (9.13%), quetiapine for 31
subjects (6.90%), aripiprazole for 30 subjects (6.68%), and other treatments for 187 subjects (41.65%). The major reason of switching treatment
was insufficient efficacy, accounting for a total of 344 subjects. AEs (92 subjects), noncompliance (51 subjects), and other (2 subjects) were the
reasons for switching. Twenty-two subjects received antipsychotics > 30 days prior to enrollment. The switching reasons were insufficient
efficacy (n = 10), side effects (n = 1), noncompliance (n = 11), and other (n = 1).
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measured by the PSP, and clinician’s overall assessment
as measured by CGI-S. Paliperidone ER was well toler-
ated in this patient population during acute treatment,
with tolerability measured by low discontinuation rates
and low adverse event burden [12,13,16]. The mainte-
nance of social functioning is important treatment
objective in the long-term management of schizophre-
nia. However, the aim of this study is to measure main-
tenance of social functioning with Personal and Social
Performance scale (PSP) to assess treatment benefit in
clinical trials. The 10-point PSP decrement is a clinically
relevant measure of maintenance of functioning in
patients stabilized with antipsychotic therapy.
Paliperidone palmitate demonstrated a statistically sig-
nificant treatment benefit in terms of maintenance of
functioning [17].
The current phase IV, open-label, prospective study
was conducted with the main objective of exploring the
relationship between achieving symptomatic remission
status by means of the 8 items of Positive and Negative
Syndrome Scale (PANSS) and personal and social func-
tioning by means of the Personal and Social Perfor-
mance (PSP) scale in patients treated with flexibly dosed
Paliperidone ER. The proportion of patients achieving
the definition of symptomatic remission status was
3.52% with 95% C.I. [1.98%, 5.74%] at baseline and
Figure 3 Summary of switching reasons of previous antipsychotic treatment of ITT population.F o rt h eI T Tp o p u l a t i o n ,t h e r ew e r e4
subjects who did not receive any antipsychotics at enrollment. For the remaining 422 subjects, 409 received antipsychotics within 30 days prior
to enrollment. The treatments included oral risperidone for 188 subjects (45.97%), olanzapine for 40 subjects (9.78%), quetiapine for 29 subjects
(7.09%), aripiprazole for 28 subjects (6.85%), and other treatments for 166 subjects (40.59%). The major reason of switching treatment was
insufficient efficacy, accounting for a total of 321 subjects. AEs (82 subjects), noncompliance (42 subjects), and other (2 subjects) were the
reasons for switching. Thirteen subjects received antipsychotics > 30 days prior to enrollment. The switching reasons were insufficient efficacy (n
= 7), noncompliance (n = 6), and other (n = 1).
Table 3 Summary of Previous Antipsychotics Treatment
Received for Consecutive 3 Months
Antipsychotic Treatments Overall
(N = 480)
ITT
(N = 426)
Oral Risperidone 224 (46.67%) 207 (48.59%)
Olanzapine 52 (10.83%) 49 (11.50%)
Quetiapine 35 (7.29%) 32 (7.51%)
Aripiprazole 30 (6.25%) 28 (6.57%)
Clozapine 14 (2.92%) 10 (2.35%)
Risperdal CONSTA 3 (0.63%) 1 (0.23%)
Other 125 (26.04%) 110 (25.82%)
Table 4 Summary of Concurrent Disease with Incidence ≧
5%
System Overall
(N = 480)
ITT
(N = 426)
Psychiatric 364 (75.83%) 329 (77.23%)
Gastrointestinal 156 (32.50%) 145 (34.04%)
Neurological 114 (23.75%) 104 (24.41%)
Cardiovascular 77 (16.04%) 74 (17.37%)
Endocrine 71 (14.79%) 62 (14.55%)
Respiratory 34 (7.08%) 31 (7.28%)
Ears, Nose, Throat 29 (6.04%) 28 (6.57%)
Musculoskeletal 32 (6.67%) 31 (7.28%)
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end of study of the ITT population.(Figure 4) The sig-
nificant improvements in personal and social function-
ing that resulted subsequent to paliperidone ER
treatment, as measured by the validated and reliable
PSP instrument may be an important clinical considera-
tion for patient treatment. Apart from improvement in
positive and negative symptoms, medications that
improve personal and social function may lead to better
social integration and overall functioning [18,19]. The
sensitivity demonstrated that the cut point 60 of PSP
scale revealed best relationship between PSP scale and
symptomatic remission. It would be useful to be able to
assess the importance of both PSP scores and changes
in PSP scores by relating them to real-life outcomes.
Ultimately, a real-life assessment of PSP scores would
have to be addressed by long-term observational studies
incorporating relatively objective measures of social
functioning, possibly drawing on multiple observers (e.
g., clinicians, family members, friends, caregivers) as
well as patient self-assessment [20-23]. The PSP may be
a useful tool to assess social functioning and importantly
to predict relapse, enabling management teams to inter-
vene before the deleterious clinical and economic
impact of relapse negatively affects the patient’sc o u r s e
of illness. The high predictive value of the PSP criteria
and relapse is particularly relevant in an illness such as
schizophrenia where noncompliance and partial compli-
ance to medication is substantial [24,25]. Patients with
schizophrenia may present with negative, cognitive, dis-
organization and mood symptoms, which persist during
periods of acute exacerbation when more overt positive
symptoms are evident. The post-hoc analysis showed
that acutely ill patients with or without predominant
negative symptoms respond similarly to treatment with
paliperidone ER [26].
The safety profile also demonstrated that paliperidone
ER was well-tolerated without clinically significant
changes after treatment administration. The most fre-
quently reported adverse event was disease progression
(33 patients, 7.7%), upper respiratory tract infection (30
patients, 7.0%), extrapyramidal disorder (25 patients,
5.2%), insomnia (17 patients, 4.0%) and constipation (14
patients, 3.3%). As well, one patient committed suicide,
and another attempted suicide and was comatose in a
vegetative state. Vital signs, such as weight, SBP, DBP,
and pulse had no clinically significant change. Various
clinical studies have demonstr a t e dt h a tp a l i p e r i d o n eE R
is safe and well-tolerated and have similar adverse event
profile. Pooled safety data indicated that paliperidone
ER was generally well tolerated. Discontinuations related
to treatment-emergent AEs were similarly low for
patients receiving paliperidone ER or placebo. Although
the incidence of EPS-related AEs was higher in paliperi-
done ER-treated patients, primarily those receiving
higher doses, the severity of EPS was very low through-
out the study [27]. Therefore, no safety concerns were
raised in this study [28]. In this study, short-term treat-
ment with paliperidone ER significantly improved psy-
chiatric symptoms and functioning, with no unexpected
safety or tolerability findings. Paliperidone is the active
metabolite of risperidone, and nearly half of the subjects
were on risperidone prior to study entry. Oral risperi-
done may have failed to provide adequate efficacy in
patients even though it is metabolized to paliperidone
because of the short plasma half-life of paliperidone.
This would make the case that paliperidone ER treat-
ment would be more effective since it stays in blood cir-
culation for an extended period of time and hence, the
controlled drug release from the osmotic drug delivery
system demonstrates clear formulation benefits as high-
lighted specifically in the title of this study. The
Table 5 Summary of Dose Disposition of ITT Population
ITT Population Initial Dose
3 mg/day 6 mg/day 9 mg/day 12 mg/day
Dose at the End of Study 3 mg/day 50 7 0 0
6 mg/day 69 152 0 0
9 mg/day 17 43 18 0
12 mg/day 18 30 11 11
Table 6 Summary of Dose Disposition of Complete Study Subjects
Complete Study Subjects Initial Dose
3 mg/day 6 mg/day 9 mg/day 12 mg/day
Dose at the End of Study 3 mg/day 40 5 0 0
6 mg/day 61 122 0 0
9 mg/day 11 42 11 0
12 mg/day 15 26 8 9
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[1.98%, 5.74%] at baseline and improved to 11.74% with
95% C.I. [8.84%, 15.18%] at the end of study (p-value <
0.05). The results demonstrated an improvement in
symptomatic remission rate after the 12-week treatment
of paliperidone ER. Another study showed that the
remission rate was increased from 43.9% at baseline to
51.7% at 12 weeks after aripiprazole treatment [29]. The
original RSWG criteria requires 6 month duration, we
have not used the criteria for remission as originally
defined. There are three key limitations to the study.
These are as follows. First, the study is the short study
design. The study attempts to explore the relationship
between symptomatic remission and function, however,
this aspect of the investigation requires additional
assessment for validity. A third limitation is the hetero-
geneous nature of the population, with some patients
being remitted at baseline. Prospectively designed and
longer-term studies are needed to further assess this
finding.
Conclusions
The diminished social functioning in schizophrenia is
probably responsible for more burdens in patients,
families, and care systems than residual symptoms.
*: p-value of change from baseline <0.05   
Figure 4 Summary of Efficacy Result. The symptomatic remission rate was 3.5% (95%CI, 1.98%, 5.74%) at baseline and improved to 11.7%
(95%CI, 8.84%, 15.18%) at the end of study (p < 0.05). The criteria for PSP improvement was at least one 10-point interval on PSP scale. In the
ITT population, subjects showed an increasing PSP improvement after treatment began. The improvement rate was increased from 28.1% (95%
CI, 23.94%, 32.70%) at week 4 to 47.4% (95%CI, 42.59%, 52.28%) at the end of study.
Table 7 Adverse Events with Incidence ≧ 2%
Preferred Term N = 426
N (%)
Patients with any Adverse Event 213 (50.0%)
Disease progression 33 (7.7%)*
Upper respiratory tract infection 30 (7.0%)
Extrapyramidal disorder 22 (5.2%)
Insomnia 17 (4.0%)
Constipation 14 (3.3%)
Anxiety 11 (2.6%)
Nasopharyngitis 11 (2.6%)
Diarrhoea 9 (2.1%)
Headache 9 (2.1%)
Somnolence 9 (2.1%)
Tachycardia 9 (2.1%)
*27 events were recorded as serious adverse events.
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Page 9 of 11Finding a psychotropic treatment that improves social
functioning is critically important. The clinical program
of paliperidone ER was designed to incorporate the PSP
as a measure of social functioning [30]. The result
showed that the 11.74% patients with at least moderate
severity of schizophrenia were evaluated as “mild” or
better on PANSS scale by all 8 items after 12 weeks of
treatment with paliperidone ER. There were also signifi-
cant improvement in patients’ functionality as measured
by PSP improvement and score changes. The cut point
60 of PSP scale revealed best relationship between PSP
scale and symptomatic remission. Besides, PANSS scale
revealed better correlation with PSP scale rather than
social functioning scale. Safety profile was also accepta-
ble. This 12-week, multi-center, open-label; prospective
study established the efficacy, safety, and tolerability of
paliperidone ER and significantly showed that symptom
severity and social functioning improve with paliperi-
done ER treatment. In the future, the correlations
between PSP and PANSS to prove the close interplay
between social functioning and psychopathology in the
chronic course of schizophrenia should be further evalu-
ated. The interaction of psychopathological states and
psychosocial functioning determines the long-term
course of schizophrenia and its treatment.
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